#	Pagina
attuale pagina	/open-h2020/projects/217301/index.html

Opendata, web and dolomites

Safe-Blood SIGNED

A cost and time effective blood test to detect multiple bloodborne diseases

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

Safe-Blood project word cloud

Explore the words cloud of the Safe-Blood project. It provides you a very rough idea of what is the project "Safe-Blood" about.

diseases equal disease single engagement laboratory 250 hiv 2024 screened disrupt 2 donation continuous 400 founded benefit tests questionnaire screening solely global struggle banks responsible infections grow collected blood alone annual reducing swiss diagnose infectious chagas 2015 htlv expertise carries money wama union company donors stakeholder transmitted vitro lives rate convert simultaneously sufficient affordable demonstrates multiple market business feasibility donations diagnostics screen carriers smei time syphilis prevent subsequently model 15 annually ambition risk hold transfusion reduce monoplex donor compound billion save hepatitis life preliminary multiplex thousands competition players collection position threatening involvement excluded supply commercial million transmit safe

Project "Safe-Blood" data sheet

The following table provides information about the project.

Coordinator	WAMA DIAGNOSTICS (SWITZERLAND) SA Organization address address: ROUTE DE L'ILE-AU-BOIS 1A city: MONTHEY postcode: 1870 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Switzerland [CH]
Project website	http://www.wamadiagnostics.ch/
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
Code Call	H2020-SMEInst-2018-2020-1
Funding Scheme	SME-1
Starting year	2018
Duration (year-month-day)	from 2018-09-01 to 2019-02-28

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	WAMA DIAGNOSTICS (SWITZERLAND) SA WAMA DIAGNOSTICS (SWITZERLAND) SA Organization address address: ROUTE DE L'ILE-AU-BOIS 1A city: MONTHEY postcode: 1870 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	CH (MONTHEY)	coordinator	50˙000.00

Map

Project objective

In the European Union alone, 15 million blood donations are collected annually, but supply of sufficient and safe donor blood remains a continuous struggle. Blood can save lives; however, it also carries the potential to transmit life-threatening infections. Potential donors are screened using a questionnaire aimed to identify risk carriers. As risk carriers do not equal disease carriers, thousands of potential donors are excluded to prevent one single case of a transfusion-transmitted disease. Subsequently, blood donations are screened for infectious diseases in the laboratory with one test for each disease.

WAMA Diagnostics is a Swiss-founded company with the ambition to disrupt the in vitro diagnostics market with affordable and reliable tests to diagnose infectious diseases. WAMA has the expertise and technology to convert multiple tests into one single test, reducing time and money. WAMA is developing the Safe-Blood test to simultaneously screen for HIV, Hepatitis B, Hepatitis C, Syphilis, HTLV and Chagas in a single test. Our preliminary cost-benefit analysis demonstrates the potential to reduce the screening costs from €70 - €250 per donor to €15 per donor.

1,400 European blood donation banks are responsible for the collection of the 15 million blood donations per year. The global blood screening market is expected to grow from €1.3 billion in 2015 with a Compound Annual Growth Rate of 10.2% to €3.1 billion in 2024. The competition is offering solely monoplex tests: one test for one disease. There are currently no players on the blood screening market that use multiplex tests to screen for multiple diseases simultaneously, and the Safe-Blood test will hold a unique position in the market.

WAMA will use the SMEi phase 1 funding to assess the feasibility and commercial potential of Safe-Blood via a user involvement study, a stakeholder engagement study, and a market study to identify the best business model to be applied in the EU.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SAFE-BLOOD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SAFE-BLOOD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MEDIVAC (2019)

Machine learning software to design personalized neoantigen vaccines tailored to specific vaccine delivery systems

RDNA (2019)

Empowering New Venture Growth - RDNA

Project Tracworx (2019)

Tracworx is a data analytics tool that allows you to establish bottlenecks in your patient flow, while understanding your efficiencies and ultimately your true capacity.